Shionogi sets out position on antimicrobial resistance

13 May 2019

Japanese drugmaker Shionogi (TYO: 4507) says it has prepared and released its “Shionogi AMR Position Paper.”

Antimicrobial resistance (AMR) is a global threat, with some reports saying that it could cause up to 10 million fatalities annually by 2050 unless we take measures against it. Regarding this social challenge against AMR, this AMR Position Paper details the point of view and efforts of Shionogi, which has been tackling the issue of drug-resistant bacteria for many years with a focus on infections.

Shionogi considers it necessary to take the following actions against AMR:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK